DRG 684 Overview

DRG 684 covers inpatient admissions for renal failure without a major complication or comorbidity and without a complication or comorbidity. It includes patients treated for acute or chronic renal insufficiency when no higher-severity diagnoses are present. This Diagnosis-Related Group matters for Medicare payment because it groups cases of moderate clinical complexity into a standardized reimbursement pathway under prospective payment. Accurate coding of renal failure and exclusion of Major Complication or Comorbidity and Complication or Comorbidity affects case assignment and payment level.

Benchmark payments across commercial payers span roughly from about $1.1K (BCBS p25) up to $24K (Anthem max), with payer medians generally between about $5.7K and $11K. The widest spread appears between Anthem’s maximum ($24K) and BCBS’s lower quartile (~$1.1K), indicating considerable variation across payers. See the table and chart below for payer-specific distributions and percentile detail.

The CMS 2023 data represent national Medicare fee-for-service inpatient payments published under the CMS Provider Utilization and Payment Data program. The table below shows average total payment, average submitted covered charges, average Medicare payment amount, and total discharges for DRG 684. Values reflect national aggregates for Medicare FFS cases in 2023.

• Acute supportive care trials investigating timing and modality of renal replacement therapy (RRT) for hospitalized patients with acute renal failure without major comorbid complications. These studies enroll adult inpatients with new-onset acute kidney injury attributed to sepsis, ischemia, or nephrotoxins who do not meet criteria for CC/MCC, comparing early versus standard initiation of intermittent versus continuous RRT or optimized conservative management. Findings inform acute management protocols, resource utilization in the inpatient setting, and short-term costs that directly affect DRG-level reimbursement and bed-level planning for hospitals and payers.
• Comparative effectiveness research comparing fluid management strategies, diuretic protocols, and nephrotoxin stewardship to prevent progression of renal dysfunction in medical and surgical inpatients. Trials or pragmatic studies focus on heterogeneous ward and ICU populations without major complications, assessing outcomes such as recovery of renal function, need for RRT, length of stay, and readmission rates. This research is relevant to clinicians and payers because modest changes in progression rates and LOS among this DRG cohort can substantially impact hospitalization costs and downstream utilization.
• Post-discharge outcomes and care-transition studies tracking recovery trajectories, outpatient follow-up strategies, and readmission prevention for patients discharged after an episode of renal failure without CC/MCC. Cohort studies and interventional trials evaluate models like early nephrology follow-up, home-based monitoring of kidney function and medication reconciliation, and patient education to reduce 30–90 day readmissions and progression to chronic kidney disease. Results guide discharge planning, bundled payments, and payer decisions about coverage for post-acute services that can reduce avoidable rehospitalizations and long-term dialysis initiation.